PURPOSE: The purpose of the study was to assess the impact of age on the pharmacokinetics of immunosuppressive drugs. METHODS: One hundred and ten renal transplant recipients, including 12 elderly patients over 60 years of age, 57 middle-aged patients between 40 and 59 years and 41 young adult patients 20 to 39 years of age were studied. To evaluate dose-adjusted pharmacokinetics and cytochrome P450 (CYP) 3A5 pharmacogenetics, the concentrations of tacrolimus, mycophenolic acid (MPA), MPA glucuronide (MPAG) and prednisolone were measured at 1 month post-transplantation. RESULTS: There were no differences in dose (D) and body weight (BW)-adjusted pharmacokinetic parameters of tacrolimus among the three groups. D/BW-adjusted C(max), C(0) and AUC(0-12) values of tacrolimus were significantly greater in patients with the CYP3A5*3/*3 genotype than in those with the CYP3A5*1 allele in young and middle-aged patients as previously reported, but not in the elderly. There were no significant differences in the D-adjusted pharmacokinetics of prednisolone and MPA among the three groups. CONCLUSION: The aging process itself may have a small effect on the pharmacokinetics of tacrolimus, MPA, or prednisolone. However, a larger number of subjects need to be studied to confirm the impact of age on the CYP3A5 pharmacogenetics of tacrolimus in the elderly.
PURPOSE: The purpose of the study was to assess the impact of age on the pharmacokinetics of immunosuppressive drugs. METHODS: One hundred and ten renal transplant recipients, including 12 elderly patients over 60 years of age, 57 middle-aged patients between 40 and 59 years and 41 young adult patients 20 to 39 years of age were studied. To evaluate dose-adjusted pharmacokinetics and cytochrome P450 (CYP) 3A5 pharmacogenetics, the concentrations of tacrolimus, mycophenolic acid (MPA), MPA glucuronide (MPAG) and prednisolone were measured at 1 month post-transplantation. RESULTS: There were no differences in dose (D) and body weight (BW)-adjusted pharmacokinetic parameters of tacrolimus among the three groups. D/BW-adjusted C(max), C(0) and AUC(0-12) values of tacrolimus were significantly greater in patients with the CYP3A5*3/*3 genotype than in those with the CYP3A5*1 allele in young and middle-aged patients as previously reported, but not in the elderly. There were no significant differences in the D-adjusted pharmacokinetics of prednisolone and MPA among the three groups. CONCLUSION: The aging process itself may have a small effect on the pharmacokinetics of tacrolimus, MPA, or prednisolone. However, a larger number of subjects need to be studied to confirm the impact of age on the CYP3A5 pharmacogenetics of tacrolimus in the elderly.
Authors: E Hustert; M Haberl; O Burk; R Wolbold; Y Q He; K Klein; A C Nuessler; P Neuhaus; J Klattig; R Eiselt; I Koch; A Zibat; J Brockmöller; J R Halpert; U M Zanger; L Wojnowski Journal: Pharmacogenetics Date: 2001-12
Authors: Michel Mourad; Pierre Wallemacq; Martine De Meyer; Dimitri Brandt; Valérie Van Kerkhove; Jacques Malaise; Djamila Chaïb Eddour; Dominique Lison; Vincent Haufroid Journal: Clin Chem Lab Med Date: 2006 Impact factor: 3.694
Authors: C X Wang; F H Meng; L Z Chen; B Ren; S X Li; J G Fei; J Qiu; S X Deng; J Li; S Y Chen Journal: Transplant Proc Date: 2007-06 Impact factor: 1.066
Authors: Jiang-Tao Tang; Brenda C de Winter; Dennis A Hesselink; Ferdi Sombogaard; Lan-Lan Wang; Teun van Gelder Journal: Br J Clin Pharmacol Date: 2016-11-30 Impact factor: 4.335
Authors: L Rojas; I Neumann; M José Herrero; V Bosó; J Reig; J Luis Poveda; J Megías; S Bea; S F Aliño Journal: Pharmacogenomics J Date: 2014-09-09 Impact factor: 3.550
Authors: Felix Krenzien; Abdallah ElKhal; Markus Quante; Hector Rodriguez Cetina Biefer; Uehara Hirofumi; Steven Gabardi; Stefan G Tullius Journal: Transplantation Date: 2015-11 Impact factor: 4.939
Authors: M Abecassis; N D Bridges; C J Clancy; M A Dew; B Eldadah; M J Englesbe; M F Flessner; J C Frank; J Friedewald; J Gill; C Gries; J B Halter; E L Hartmann; W R Hazzard; F M Horne; J Hosenpud; P Jacobson; B L Kasiske; J Lake; R Loomba; P N Malani; T M Moore; A Murray; M-H Nguyen; N R Powe; P P Reese; H Reynolds; M D Samaniego; K E Schmader; D L Segev; A S Shah; L G Singer; J A Sosa; Z A Stewart; J C Tan; W W Williams; D W Zaas; K P High Journal: Am J Transplant Date: 2012-09-07 Impact factor: 8.086
Authors: Amelia R Cossart; Nicole M Isbel; Carla Scuderi; Scott B Campbell; Christine E Staatz Journal: Front Pharmacol Date: 2021-04-12 Impact factor: 5.810
Authors: K Sanghavi; R C Brundage; M B Miller; D P Schladt; A K Israni; W Guan; W S Oetting; R B Mannon; R P Remmel; A J Matas; P A Jacobson Journal: Pharmacogenomics J Date: 2015-12-15 Impact factor: 3.550